Associated Papers
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Herencia-Ropero A et al.
Genome Medicine, 2024
39187844 (PubMed )
Supplement: 13073_2024_1370_MOESM3_ESM.xlsx › SNV
Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes.
Cereda M et al.
Nature Communications, 2016
27377421 (PubMed )
Supplement: ncomms12072-s2.xlsx › S6T2
A Bayesian ensemble approach with a disease gene network predicts damaging effects of missense variants of human cancers.
Won HH et al.
Human Genetics, 2013
The genomic landscapes of human breast and colorectal cancers.
Wood LD et al.
Science (new York, N.y.), 2007
17932254 (PubMed )
Supplement: 1145720s_tables.zip › 1145720tableS3.xls › Both
The consensus coding sequences of human breast and colorectal cancers.
Sjöblom T et al.
Science (new York, N.y.), 2006
16959974 (PubMed )
Supplement: 1133427_som_tables.zip › Table_S4_-__Somatic_mutations_identified_in_breast_and_colorectal_cancers_8-29-06.xls › Sheet1
Select a paper to view details